Global Initiative Launches Access to Essential Childhood Cancer Medicines

By João L. Carapinha

March 25, 2025

The World Health Organization (WHO) and St. Jude Children’s Research Hospital have launched a major effort to distribute essential childhood cancer medicines. This initiative is part of a new Global Platform targeting low- and middle-income countries (LMICs). It aims to deliver a consistent supply of quality-assured cancer drugs at no cost. The goal is to reach 50 countries within the next 5-7 years.

Current Progress and Reach

The platform is currently providing medicines to Mongolia and Uzbekistan. They also have planned shipments for Ecuador, Jordan, Nepal, and Zambia. The WHO and St. Jude Children’s Research Hospital expect to reach approximately 120,000 children diagnosed with cancer in low- and middle-income countries (LMICs). This marks the first large-scale effort of its kind, as they unite governments, the pharmaceutical industry, and NGOs to ensure consistent access to quality childhood cancer medicines.

Addressing Survival Disparities

Childhood cancer survival rates in low- and middle-income countries often fall below 30%. In high-income countries, rates exceed 80%. The WHO Global Initiative for Childhood Cancer, launched in 2018, aims to increase survival rates for six treatable cancers to 60% by 2030 in participating nations.

Potential for Transformative Change

This initiative could significantly advance health economics and outcomes research. It will improve data collection on childhood cancer treatment and outcomes in resource-limited settings. It may also reduce healthcare costs linked to inconsistent or inadequate cancer treatment. The platform’s strategy of consolidating demand for childhood cancer medicines could reshape pricing and procurement strategies for other vital drugs in low- and middle-income countries.

For further details on this essential initiative, you can explore the original article from the WHO.

Reference url

Recent Posts

Impact of Generic Liraglutide Launch on Weight Management and Health Economics

By João L. Carapinha

September 3, 2025

Teva’s recent announcement of the U.S. Food and Drug Administration (FDA) approval and the generic liraglutide launch marks a significant development in the weight-loss therapeutics market. The introduction of the first generic version of Saxenda (liraglutide) injection highlights both a critical...
Collaboration Cardiac Surgery: Boosting Surgical Volumes Through Multidisciplinary Teams

By João L. Carapinha

September 1, 2025

Cardiovascular Business recently examines how closer collaboration cardiac surgery between interventional cardiologists and cardiac surgeons can increase patient referrals for surgical interventions. This is especially important as less-invasive procedures like transcatheter interventions grow in...
Mounjaro Price Increase UK: Impacts on Access and Health Economics
Eli Lilly is raising Mounjaro's UK price by 170% on September 1, 2025. The highest dose will jump from £122 to £330 monthly. But the company has negotiated discounts with pharmacies. This will lower the effective price to £247.50. This hike aims to align international pricing as it responds to pr...